A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Advanced and/or Metastatic Solid Organ Cancer Clinical Trial

Official title: A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer

Status Active, not recruiting

Clinical Trial Summary

Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer

Clinical Trial Description

Nine Cohorts of dose escalating VB-111 were completed with a total of 56 subjects enrolled. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced and/or Metastatic Solid Organ Cancer
• Neoplasm Metastasis

• NCT number: NCT00559117
• Study type: Interventional
• Source: Vascular Biogenics Ltd. operating as VBL Therapeutics
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: November 2007
• Completion date: June 2015